Search alternatives:
significant estimated » significant estimates (Expand Search), significantly mitigated (Expand Search), significantly overestimated (Expand Search)
significant effects » significant effect (Expand Search), significantly affected (Expand Search)
Showing 161 - 180 results of 44,070 for search '(( significant estimated decrease ) OR ( significant effects decrease ))', query time: 1.69s Refine Results
  1. 161
    Chemicals that decrease the expression levels of significant TWAS genes negatively associated with UF.

    Chemicals that decrease the expression levels of significant TWAS genes negatively associated with UF. by Gayeon Kim (671557)

    Published 2022
    Save to List
    Saved in:
  2. 162
    Odds ratios and 95% confidence intervals of micronutrient intakes below the estimated average requirement (EAR) in men according to frailty groups.

    Odds ratios and 95% confidence intervals of micronutrient intakes below the estimated average requirement (EAR) in men according to frailty groups. by Subeen Kim (11714313)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 163
    Odds ratios and 95% confidence intervals of micronutrient intakes below the estimated average requirement (EAR) in women according to frailty groups.

    Odds ratios and 95% confidence intervals of micronutrient intakes below the estimated average requirement (EAR) in women according to frailty groups. by Subeen Kim (11714313)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 164
    Mean r<sup>2</sup> estimates at different physical distances for different sample size.

    Mean r<sup>2</sup> estimates at different physical distances for different sample size. by Akansha Singh (669369)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  5. 165
    Repeated test results of different depth estimation methods under waveguide conditions in Qingdao’s shallow waters.

    Repeated test results of different depth estimation methods under waveguide conditions in Qingdao’s shallow waters. by Du Siqi (20721422)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 166
    Comparison of the results of different methods for estimating the depth of the sound source of measured airguns in the experimental sea area.

    Comparison of the results of different methods for estimating the depth of the sound source of measured airguns in the experimental sea area. by Du Siqi (20721422)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 167
    Sensitivity statistics of WMD analysis of PC between PE and NT groups.

    Sensitivity statistics of WMD analysis of PC between PE and NT groups. by Muluken Walle (13794209)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 168
    Flow chart to describe the selection of studies for the systematic review and meta-analysis on the association between PC and MPV with PE.

    Flow chart to describe the selection of studies for the systematic review and meta-analysis on the association between PC and MPV with PE. by Muluken Walle (13794209)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 169
    Sensitivity statistics of included studies for WMD analysis of MPV.

    Sensitivity statistics of included studies for WMD analysis of MPV. by Muluken Walle (13794209)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 170
    Dose determination and cell viability estimation of (A) NF-Orientin and (B) Native Orientin using MCF-7 cell lines.

    Dose determination and cell viability estimation of (A) NF-Orientin and (B) Native Orientin using MCF-7 cell lines. by Yashwanth Elumalai (21743452)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 171
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 172
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 173
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 174
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 175
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 176
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 177
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 178
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 179
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 180
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: